Abstract

BackgroundPre-treatment evaluation for sarcopenia is recommended in cancer patients. New screening tests that are less time-consuming and can identify patients who will potentially benefit from geriatric assessment are being developed; the G8 geriatric screening test is one such example. We aimed to investigate whether the G8 screening test can detect probable sarcopenia and is valid and reliable compared to a comprehensive geriatric assessment (CGA) in Turkish older adults with solid cancers.MethodsWe included solid cancer patients referred to a single center. Probable sarcopenia and abnormal CGA were defined as low handgrip strength. Cut-offs for handgrip strength in the Turkish population have been previously determined to be 32 kg for males and 22 kg for females and impairment in at least one of the CGA tests, respectively. The CGA tests comprised KATZ Basic Activities of Daily Living Scale Lawton–Brody Instrumental Activities of Daily Living Scale, Mini-Mental-State Examination Scale, Geriatric Depression Scale-15, and Mini-Nutritional Assessment Short Form. Receiver operating characteristic curve analyses evaluated the test’s predictive ability. Intra-rater and inter-rater reliabilities were assessed.ResultsThe median age of the 76 patients included was 72 (65–91) years. There was a moderate correlation between handgrip strength and the G8 test total score. The sensitivity and specificity of the G8 test to detect probable sarcopenia alone (cut off score = 12.5) were 50 and 92%, respectively (AUC: 0.747; p < 0.001); to determine abnormal CGA plus probable sarcopenia (cut off score = 13) were 93.33 and 86.89%, respectively (AUC: 0.939; p < 0.001); and to detect abnormal CGA alone (cut off score = 14) were 79.63 and 95.45%, respectively (AUC: 0.893; p < 0.001). The G8 test results agreed with those of CGA (κ = 0.638; p < 0.001). Both inter- and intra-rater assessments of G8 scores revealed a strong agreement (Interclass correlation coefficient = 0.979, p < 0.001 and ρ = 0.994, p < 0.001, respectively).ConclusionsThe Turkish version of the G8 test is a good screening tool to detect probable sarcopenia alone and in conjunction with abnormal CGA in older patients with solid malignancies. The G8 screening tool may thus be useful in detecting probable sarcopenia in Turkish older adults with solid cancers.

Highlights

  • Oncologists must consider the possibility of adverse events like chemotherapy-induced toxicities, hospitalization, and early death when planning cancer treatment in older adults [1, 2]

  • The G8 screening tool may be useful in detecting probable sarcopenia in Turkish older adults with solid cancers

  • The G8 geriatric screening test is successful in indicating the need for comprehensive geriatric assessment (CGA), its ability to screen for sarcopenia has not yet been investigated

Read more

Summary

Introduction

Oncologists must consider the possibility of adverse events like chemotherapy-induced toxicities, hospitalization, and early death when planning cancer treatment in older adults [1, 2]. CGAs are shown to improve the disease-related outcome, increase treatment efficacy, minimize chemotherapy-induced toxicity, and decrease the risk of falls among cancer patients. The G8 geriatric screening test, developed by Bellera et al in 2012, assesses the nutritional status, mobility, age, general health status, neuropsychological status, and drug usage in cancer patients [7]. The G8 geriatric screening test is successful in indicating the need for CGA, its ability to screen for sarcopenia has not yet been investigated. Pre-treatment evaluation for sarcopenia along with CGA has been recommended in cancer patients. Pre-treatment evaluation for sarcopenia is recommended in cancer patients. We aimed to investigate whether the G8 screening test can detect probable sarcopenia and is valid and reliable compared to a comprehensive geriatric assessment (CGA) in Turkish older adults with solid cancers

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call